drugset / Trial / NCT05147415

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

NCT05147415

Phase 2 Withdrawn Saniona
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO

Timeline

Start
2021-11-11
Primary completion
2022-12-09
Completion
2022-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified Oral
Subject Tesofensine Small molecule Oral